PMID- 15967250
OWN - NLM
STAT- MEDLINE
DCOM- 20051027
LR  - 20181201
IS  - 0302-2838 (Print)
IS  - 0302-2838 (Linking)
VI  - 48
IP  - 1
DP  - 2005 Jul
TI  - PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy 
      for localized prostate adenocarcinoma and the relationship with the kinetics of 
      testosterone.
PG  - 40-5
AB  - OBJECTIVES: To assess the factors effecting PSA bounce and to identify any 
      possible relationship with biochemical control after 3-D conformal radiotherapy 
      (3D-CRT) and total androgen deprivation (TAD) for prostate cancer by evaluating 
      four previously described PSA bounce definitions. METHODS: Between January 1998 
      and January 2001, 83 consecutive patients with clinically localized prostate 
      cancer were treated by 3D-CRT with neoadjuvant 3 months and/or 6 months adjuvant 
      TAD. All patients had a pretreatment PSA level, at least eight post-external beam 
      radiotherapy (EBRT) PSA and testosterone levels and minimum two years of 
      follow-up. Total radiotherapy dose was 73.6 Gy at ICRU reference point. Four 
      previous definitions of PSA bounce were used: Critz definition (>or=0.1 ng/mL), 
      Cavanagh definition (>or=0.2 ng/mL), Hanlon definition (>or=0.4 ng/mL) and Rosser 
      definition (>or=0.5 ng/mL) according to original methodology performed to report 
      PSA bounce. Biochemical failure was defined in accordance with the ASTRO 
      consensus guidelines. RESULTS: The median follow-up time was 40 months. PSA 
      bounce was recorded as follows: Critz definition, 33 patients (40%); Cavanagh 
      definition, 21 patients (25%); Hanlon definition, 11 patients (13%); and Rosser 
      definition, 7 patients (8%). In multivariate analysis, pre-EBRT PSA level and the 
      duration of TAD for Critz definition; age, pre-EBRT PSA and the duration of TAD 
      for Cavanagh definition; age and duration of TAD for Hanlon definition; age and 
      pre-biopsy PSA for Rosser definition were significant independent prognostic 
      factors determining PSA bounce. A significant increase of mean testosterone level 
      in bouncers was detected at the 6th-9th and 18th-21st months. PSA bounce did not 
      predict for PSA failure in multivariate analysis. CONCLUSIONS: We observed no 
      correlation between biochemical failure and PSA bounce. The longer duration of 
      TAD and older age were found to be inversely proportional with PSA bouncing in 
      this cohort. Notably, recovery of testosterone might cause PSA bouncing.
FAU - Akyol, Fadil
AU  - Akyol F
AD  - Faculty of Medicine, Department of Radiation Oncology, Hacettepe University, 
      Ankara, Turkey.
FAU - Ozyigit, Gokhan
AU  - Ozyigit G
FAU - Selek, Ugur
AU  - Selek U
FAU - Karabulut, Erdem
AU  - Karabulut E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20050418
PL  - Switzerland
TA  - Eur Urol
JT  - European urology
JID - 7512719
RN  - 0 (Androgens)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 08AN7WA2G0 (Triptorelin Pamoate)
RN  - 0F65R8P09N (Goserelin)
RN  - 3XMK78S47O (Testosterone)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/blood/pathology/*radiotherapy
MH  - Aged
MH  - Androgens/*therapeutic use
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Disease Progression
MH  - Follow-Up Studies
MH  - Goserelin/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/blood/pathology/*radiotherapy
MH  - Radiotherapy, Adjuvant
MH  - Radiotherapy, Conformal/*methods
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - Testosterone/*blood
MH  - Time Factors
MH  - Treatment Outcome
MH  - Triptorelin Pamoate/therapeutic use
EDAT- 2005/06/22 09:00
MHDA- 2005/10/28 09:00
CRDT- 2005/06/22 09:00
PHST- 2004/12/10 00:00 [received]
PHST- 2005/04/06 00:00 [accepted]
PHST- 2005/06/22 09:00 [pubmed]
PHST- 2005/10/28 09:00 [medline]
PHST- 2005/06/22 09:00 [entrez]
AID - S0302-2838(05)00214-9 [pii]
AID - 10.1016/j.eururo.2005.04.007 [doi]
PST - ppublish
SO  - Eur Urol. 2005 Jul;48(1):40-5. doi: 10.1016/j.eururo.2005.04.007. Epub 2005 Apr 
      18.